Quinn Opportunity Partners LLC Has $1.47 Million Holdings in CureVac N.V. $CVAC

Quinn Opportunity Partners LLC increased its stake in shares of CureVac N.V. (NASDAQ:CVAC) by 305.3% during the second quarter, HoldingsChannel reports. The institutional investor owned 270,911 shares of the company’s stock after buying an additional 204,073 shares during the quarter. Quinn Opportunity Partners LLC’s holdings in CureVac were worth $1,471,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Ballentine Partners LLC increased its stake in CureVac by 81.8% in the first quarter. Ballentine Partners LLC now owns 31,573 shares of the company’s stock valued at $88,000 after acquiring an additional 14,210 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of CureVac by 14.3% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,125 shares of the company’s stock valued at $81,000 after purchasing an additional 3,648 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of CureVac during the 1st quarter worth $853,000. Deutsche Bank AG lifted its position in shares of CureVac by 35.9% during the 1st quarter. Deutsche Bank AG now owns 230,813 shares of the company’s stock worth $639,000 after buying an additional 60,941 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in CureVac in the first quarter valued at about $232,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

CureVac Stock Up 1.1%

Shares of NASDAQ:CVAC opened at $5.34 on Thursday. The firm has a market cap of $1.20 billion, a P/E ratio of 5.56 and a beta of 2.56. CureVac N.V. has a 12-month low of $2.37 and a 12-month high of $5.72. The business has a fifty day simple moving average of $5.36 and a 200 day simple moving average of $5.06. The company has a quick ratio of 6.16, a current ratio of 6.17 and a debt-to-equity ratio of 0.05.

CureVac (NASDAQ:CVAC) last released its earnings results on Thursday, August 21st. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.15). CureVac had a net margin of 38.21% and a return on equity of 29.57%. The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $4.27 million. Analysts predict that CureVac N.V. will post 0.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “hold (c-)” rating on shares of CureVac in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $6.83.

CureVac Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.